



## Jaguar Animal Health to Participate in Biotech Showcase 2017 Week of January 9th in San Francisco

January 5, 2017

*Management will also be available to schedule meetings outside of the conference*

SAN FRANCISCO--(BUSINESS WIRE)--Jan. 5, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) ("Jaguar"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that its president and CEO, Lisa Conte, will participate in the Biotech Showcase™ 2017 conference being held in San Francisco Monday, January 9th through Wednesday, January 11th. The conference is run concurrently with, but independently from, the JP Morgan Healthcare Conference in San Francisco.

Currently, Ms. Conte is scheduled to provide a Company update during a group presentation to investors on Monday, January 9 at 4:30 PM PT. She will also be available for one-on-one meetings with new and existing analysts, investors and partners at the conference. Those interested in scheduling a one-on-one meeting with management should contact investor relations at [jaquar@kcsa.com](mailto:jaquar@kcsa.com).

### **About Jaguar Animal Health, Inc.**

Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia™ is Jaguar's lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar's prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the *Croton lechleri* tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company's lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the *Croton lechleri* tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs.

For more information, please visit [www.jaguaranimalhealth.com](http://www.jaguaranimalhealth.com).

### **Forward-Looking Statements**

Certain statements in this press release constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. These include statements regarding Jaguar's intention to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Jaguar-JAGX

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170105005874/en/>

Source: Jaguar Animal Health, Inc.

Investor Relations:  
KCSA Strategic Communications  
Garth Russell, 212-896-1250  
[grussell@kcsa.com](mailto:grussell@kcsa.com)